Peptide Reports

TB-500

Community Protocol

TB-500

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Educational and calculation-reference material only. Community reports are uncontrolled anecdotes and do not replace professional medical guidance, product labeling, or individualized clinical monitoring.

Scope

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Available strengths: 5 MG

Preparation Examples

These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.

SetupDiluentConcentrationUnit conversion
5 MG vial – 2 mL exampleAdd 2 mL bacteriostatic water2.5 mg/mLEach U-100 unit = 25 mcg
5 MG vial – 1 mL exampleAdd 1 mL bacteriostatic water5 mg/mLEach U-100 unit = 50 mcg

Syringe Conversion

Reported amount5 MG setup5 MG setup
500 mcg20 units10 units
1 mg40 units20 units
2 mg80 units40 units
5 mg200 units100 units

Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.

Community-Reported Patterns

Recurring reportFrequency seenContext in reports
2 mgTwice weeklyLower loading reports
2.5-5 mgTwice weeklyMost recurring loading range
2-5 mgEvery two to four weeksMaintenance discussions

Observations

  • Community discussions most often centered on soft-tissue recovery, mobility and injury-related goals.
  • The amount, frequency, route and cycle length varied substantially between reports.
  • Reported outcomes were commonly confounded by diet, training, other products or existing treatment.

Caveats

  • TB-500 human safety and dosing are not established; recovery claims are largely extrapolated from preclinical work.
  • Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.

Sources

  1. Community search: TB-500
  2. PubMed literature search: TB-500